A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma

Annals of Oncology

Volumn 17, Issue 12, 2006, Pages 1826-1829

  Schmittel, Alexander ^a   Schmidt Hieber, M ^a   Martus, P ^b   Bechrakis, N E ^b   Schuster, R ^a   Siehl, J M ^a   Foerster, M H ^b   Thiel, E ^a   Keilholz, U ^a  

^a Oncology and Transfusion Medicine   (Germany)

^b NONE   (Germany)

Author keywords

Gemcitabine; Randomized phase II; Treosulfan; Uveal melanoma

Indexed keywords

ANTIEMETIC AGENT; BENDAMUSTINE; BLEOMYCIN; CISPLATIN; CYTARABINE; CYTOKINE; DACARBAZINE; FOTEMUSTINE; GEMCITABINE; HISTAMINE; INTERLEUKIN 2; LACTATE DEHYDROGENASE; LOMUSTINE; SEROTONIN 3 ANTAGONIST; TREOSULFAN; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; UVEA MELANOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SURVIVAL ANALYSIS; UVEAL NEOPLASMS;

EID: 33845366470     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl309     Document Type: Article

References (24)

1. Egan KM, Seddon JM, Glynn RJ et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32: 239-251.
2. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110: 245-250.
3. Schmittel A, Bechrakis NE, Martus P et al. Independent prognostic factors for distant metastases and survival in patents with primary uveal melanoma. Eur J Cancer 2004; 40: 2389-2395.
4. Bedikian AY, Legha SS, Mavligit G et al. Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76: 1665-1670.
5. Gragoudas ES, Egan KM, Seddon JM et al. Survival of patents with metastases from uveal melanoma. Ophthalmology 1991; 98: 383-389.
6. Kath R, Hayungs J, Bornfeld N et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72: 2219-2223.
7. Schmittel A, Schuster R, Bechrakis NE et al. A two-cohort phase II trial of gemcitabine plus trosulfan in patients with metastatic uveal melanoma. Melanoma Res 2005; 15: 441-451.
8. Kodjikian L, Grange JD, Baldo S et al. Prognostic factors of liver metastases from uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2005; 243: 985-993.
9. Flaherty LE, Unger JM, Liu PY et al. Metastatic melanoma from intraocular primary tumors: The Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21: 568-572.
10. Pyrhonen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10: 1919-1926.
11. Becker JC, Terheyden P, Kampgen E et al, Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87: 840-845.
12. Kivelä T, Suciu S, Hansson J et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003; 39: 1115-1120.
13. Leyvraz S, Bosshard W, Salmon R et al. Prolonged survival of patents with liver metastases from ocular melanoma: Multicentric experience with fotemustin hepatic arterial infusion. J Clin Oncol 2002; 20: 1360.
14. Patel K, Sullivan K, Berd D et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: Results of a phase II study. Melanoma Res 2005; 15: 297-304.
15. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand crosslinking by treosulfan. Br J Cancer 1999; 79: 264-266.
16. Fritz G, Hengstler JG, Kaina B. High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: Characterization of hypersensitive cell lines. Cancer Res 1997; 57: 454-460.
17. Neale MH, Myatt N, Cree IA et al. Combination chemotherapy for choroidal melanoma: Ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79: 1487-1493.
18. Corrie PG, Shaw J, Spanswick VJ et al. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br J Cancer 2005; 92: 1997-2003.
19. Keilholz U, Schuster R, Schmittel A et al. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumors. Eur J Cancer 2004; 40: 2047-2052.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
22. Nathan FE, Bard D, Sato T et al. BOLD+interferon in the treatment of metastatic uveal melanoma: First report of active systemic therapy. J Exp Clin Cancer Res 1997; 16: 201-208.
23. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif 2001; 19: 21-45.
24. Pföhler C, Cree IA, Ugurel S et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: Results of multicenter feasibility study. Anticancer Drugs 2003; 14: 337-340.